Immunotherapy: Personalized Treatment for Advanced Prostate Cancer
In April 2010, the FDA approved sipuleucel-T for patients with castration-resistant and metastatic prostate cancer, providing a new treatment that would help the body fight its own cancer.
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Both Gastric and Breast HER2 Scoring Algorithms Applicable in mCRC Testing
Encorafenib Plus Cetuximab and Chemotherapy Demonstrates Safety, Efficacy in BRAF V600E–Mutant mCRC
2 Clarke Drive Cranbury, NJ 08512